

ASSEMBLY JOINT RESOLUTION

No. 155

STATE OF NEW JERSEY

219th LEGISLATURE

INTRODUCED MARCH 16, 2020

Sponsored by:

Assemblywoman NANCY F. MUNOZ

District 21 (Morris, Somerset and Union)

SYNOPSIS

Establishes New Jersey Pharmacogenomics Commission.

CURRENT VERSION OF TEXT

As introduced.



1 **A JOINT RESOLUTION** establishing the New Jersey
2 Pharmacogenomics Commission.

3
4 **BE IT RESOLVED** *by the Senate and General Assembly of the*
5 *State of New Jersey:*

6
7 1. a. There is established the New Jersey Pharmacogenomics
8 Commission. The commission shall be responsible for examining
9 pharmacogenomics, which is the study of the relationship between a
10 person's specific genetic makeup and the effectiveness or toxicity
11 of medications used to treat any health-care related issue. The
12 commission's examination shall include, but shall not be limited to:

13 (1) costs related to pharmacogenomic testing currently and in
14 the future;

15 (2) how implementing pharmacogenomics may benefit
16 prescribers, patients, and the State;

17 (3) various applications for pharmacogenomics outside of
18 medicine, such as the opioid crisis and others;

19 (4) the relationship between pharmacogenics applications in
20 personalized medicine;

21 (5) the results of previous studies on prescribing medicines and
22 treatments based on pharmacogenomic science;

23 (6) methods of educating patients and prescribers on prescribing
24 medicine and treatment based on genetic makeup;

25 (7) the relationship of pharmacogenomics in the reduction of the
26 number of deaths, disabilities, and hospitalization from adverse
27 drug events; and

28 (8) the expected costs and benefits from implementing
29 pharmacogenomics in the short-term and long-term.

30 b. The commission shall consist of 13 members as follows: a
31 representative from the Department of Health; a representative from
32 the Division of Pensions and Benefits in the Department of the
33 Treasury; a representative from Rutgers Medical School who is a
34 physician; a representative from Rutgers School of Pharmacy; a
35 representative from Fairleigh Dickinson School of Pharmacy and
36 Health Sciences; a representative from the New Jersey Hospital
37 Association; a representative from the Medical Society New
38 Jersey; a representative from the New Jersey Pharmacists
39 Association; a representative from the Department of Military and
40 Veterans Affairs; a representative from BioNJ; a representative
41 from the Hackensack Meridian School of Medicine at Seton Hall
42 University who is a physician; a representative from the Cooper
43 Medical School of Rowan University who is a physician; and a
44 professor of genetics.

EXPLANATION – Matter enclosed in bold-faced brackets **[thus]** in the above bill is
not enacted and is intended to be omitted in the law.

Matter underlined thus is new matter.

1 The Governor shall appoint representatives from the Department
2 of Health, the Division of Pensions and Benefits in the Department
3 of the Treasury, the Department of Military and Veterans Affairs,
4 Rutgers Medical School, Rutgers School of Pharmacy, Cooper
5 Medical School of Rowan University, and the professor of genetics.
6 The President of the Senate shall appoint representatives from
7 BioNJ, the Hackensack Meridian School of Medicine at Seton Hall
8 University, and the New Jersey Pharmacists Association. The
9 Speaker of the General Assembly shall appoint representatives from
10 the Medical of Society New Jersey, Fairleigh Dickinson School of
11 Pharmacy, and New Jersey Hospital Association. The Minority
12 Leader of the Senate shall recommend the appointment of the
13 representative from BioNJ. The Minority Leader of the General
14 Assembly shall recommend the appointment of the representative
15 from the Medical of Society New Jersey.

16 c. Vacancies in the membership of the commission shall be
17 filled as provided for the original appointments.

18 d. The commission shall organize as soon as practicable
19 following the appointment of its members and shall select a
20 chairperson from among the members. The chairperson shall
21 appoint a secretary who need not be a member of the commission.

22 e. Members of the commission shall serve without
23 compensation, but shall be reimbursed for necessary expenses
24 incurred in the performance of their duties as members of the
25 commission within the limits of funds appropriated or otherwise
26 made available to the commission for its purposes.

27 f. The commission shall be entitled to call to its assistance and
28 avail itself of the services of the employees of any State, county, or
29 municipal department, board, bureau, commission, or agency as it
30 may require and as may be available to it for its purposes.

31 g. The Department of Health shall provide staff support to the
32 commission.

33 h. (1) No later than six months after organization, the
34 commission shall hold at least two public hearings, one each in
35 northern New Jersey and southern New Jersey.

36 (2) For the purposes of this subsection, “northern New Jersey”
37 means Bergen, Essex, Hudson, Hunterdon, Middlesex, Morris,
38 Passaic, Somerset, Sussex, Union, and Warren counties; and
39 “southern New Jersey” means Atlantic, Burlington, Camden, Cape
40 May, Cumberland, Gloucester, Mercer, Monmouth, Ocean, and
41 Salem counties.

42 i. No later than six months after organization, the commission
43 shall submit to the Governor, and to the Legislature pursuant to
44 section 2 of P.L.1991, c.164 (C.52:14-19.1), a report of its findings
45 and recommendations for legislative, executive, or any other action
46 as may be appropriate. The commission shall expire upon
47 submission of its report.

1 2. This joint resolution shall take effect immediately.

2

3

4

STATEMENT

5

6 This joint resolution establishes the New Jersey
7 Pharmacogenomics Commission (commission). Under the
8 resolution, the commission is to be responsible for examining
9 pharmacogenomics, which is the study of the relationship between a
10 person's specific genetic makeup and the effectiveness or toxicity
11 of medications used to treat any health-care related issue. The
12 commission's examination is to include, but is not to be limited to:
13 (1) costs related to pharmacogenomic testing currently and in the
14 future; (2) how implementing pharmacogenomics may benefit
15 prescribers, patients, and the State; (3) various applications for
16 pharmacogenomics outside of medicine, such as the opioid crisis
17 and others; (4) the relationship between pharmacogenomics
18 applications in personalized medicine; (5) the results of previous
19 studies on prescribing medicines and treatments based on
20 pharmacogenomic science; (6) methods of educating patients and
21 prescribers on prescribing medicine and treatment based on genetic
22 makeup; (7) the relationship of pharmacogenomics in the reduction
23 of the number of deaths, disabilities, and hospitalization from
24 adverse drug events; and (8) the expected costs and benefits from
25 implementing pharmacogenomics in the short-term and long-term.

26 As amended, the commission is to consist of 13 members as
27 follows: a representative from the Department of Health; a
28 representative from the Division of Pensions and Benefits in the
29 Department of the Treasury; a representative from Rutgers Medical
30 School who is a physician; a representative from Rutgers School of
31 Pharmacy; a representative from Fairleigh Dickinson School of
32 Pharmacy and Health Sciences; a representative from the New
33 Jersey Hospital Association; a representative from the Medical of
34 Society New Jersey; a representative from the New Jersey
35 Pharmacists Association; a representative from the Department of
36 Military and Veterans Affairs; a representative from BioNJ; a
37 representative from the Hackensack Meridian School of Medicine at
38 Seton Hall University who is a physician; a representative from the
39 Cooper Medical School of Rowan University who is a physician;
40 and a professor of genetics.

41 The Governor is to appoint representatives from the Department
42 of Health, the Division of Pensions and Benefits in the Department
43 of the Treasury, the Department of Military and Veterans Affairs,
44 Rutgers Medical School, Rutgers School of Pharmacy, Cooper
45 Medical School of Rowan University, and the professor of genetics.
46 The President of the Senate is to appoint representatives from
47 BioNJ, the Hackensack Meridian School of Medicine at Seton Hall
48 University, and the New Jersey Pharmacists Association. The

1 Speaker of the General Assembly is to appoint representatives from
2 the Medical of Society New Jersey, Fairleigh Dickinson School of
3 Pharmacy, and New Jersey Hospital Association. The Minority
4 Leader of the Senate is to recommend the appointment of the
5 representative from BioNJ. The Minority Leader of the General
6 Assembly is to recommend the appointment of the representative
7 from the Medical of Society New Jersey.

8 The bill provides that, no later than six months after
9 organization, the commission is to hold at least two public hearings,
10 one each in northern New Jersey and southern New Jersey, and to
11 issue a report of its findings to the Governor and the Legislature,
12 including recommendations for legislative, executive, or any other
13 actions, as may be appropriate. The commission will expire upon
14 submission of the report.